BioAge Labs Q2 2026: $381M Cash, BGE-102 Phase 2 Underway, Insiders Adopt 10b5-1 Plans
BIOA has more than doubled off its 52-week low of $4.25.
Summary
BioAge Labs' Q2 2026 filing shows a strong cash position funding an expanding BGE-102 clinical program, while multiple top executives adopted pre-arranged stock trading plans.
Key Events · Earnings and Guidance · BIOA
-
Cash Runway Through 2029
Cash, equivalents, and marketable securities totaled $381.3 million at June 30, 2026, which management estimates funds operations and capital expenses through 2029.
-
BGE-102 Phase 2 Initiated
The QUELL-CV Phase 2 dose-ranging trial of BGE-102 in obesity and elevated cardiovascular risk began dosing in June 2026; topline data expected in the second half of 2026. A second trial in diabetic macular edema (QUELL-DME) is planned to start mid-2026.
-
R&D Spending Surges on BGE-102
Research and development expenses rose 45% to $44.8 million in H1 2026, driven by a $13.6 million increase in direct BGE-102 costs for clinical trials, manufacturing, and licensing.
-
Multiple Insiders Adopt 10b5-1 Plans
Six officers and directors—including the CEO, COO, CFO, and CMO—adopted Rule 10b5-1 trading plans in April-May 2026, covering potential sales of up to approximately 1.1 million shares at minimum prices ranging from $14.50 to $60.00 per share.
Analysis · BIOA · Life Sciences
A net loss of $48.4 million for the first half of 2026—up from $34.5 million a year ago—reflects a 45% surge in R&D spending to $44.8 million, almost entirely driven by the BGE-102 NLRP3 inhibitor program. The company dosed the first patient in the Phase 2 QUELL-CV trial in June and plans to start a second proof-of-concept trial in diabetic macular edema by mid-2026. With $381.3 million in cash and securities, management says the runway extends through 2029. Against that backdrop, six insiders—including the CEO, COO, CFO, and CMO—adopted 10b5-1 trading plans in April and May, covering up to roughly 1.1 million shares at minimum prices well above the current $10.98. The plans are pre-set and do not signal imminent selling, but the sheer number of officers adopting plans simultaneously is notable. The securities class action appeal is also advancing, with the plaintiff's opening brief filed in July and the company's response due in September.
At the time of this filing, BIOA was trading at $10.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $488.1M. The 52-week trading range was $4.25 to $25.96. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.